HIV/AIDS Vaccines

Some propelled stage clinical trials of HIV immunization are continuous. Even though the production of a compelling HIV-1 antibody remains a tremendous test, the proceeding with advance in these zones gives motivation to be idealistic about our definitive capacity to control the spread of AIDS. Development of a HIV/AIDS immunization has been easing back on the grounds that established ways to deal with antibody improvement have not yielded an antibody.

 

  • Age acceleration effects due to HIV infection
  • Attenuated Virus Vaccines in HIV Infection
  • HIV stems vaccination
  • HIV Vaccine development from Animal Models
  • Microbicides for sexually Transmitted Diseases
  • Recombinant vector vaccine

Related Conference of HIV/AIDS Vaccines

October 25-26, 2019

37thVaccination, Immunization & Antibiotics

Vancouver, Canada
November 12-13, 2019

35th World Vaccines & Immunization Congress

Brisbane, Australia

HIV/AIDS Vaccines Conference Speakers

Recommended Sessions

Related Journals

Are you interested in